

Nrf2-Targeting Small Molecule Candidate Development for Parkinson's Disease

SPARK Biopharma Inc.



NEUROLOGY	Candidate
Product Type	Small molecule
Indication	Parkinson's Disease
Target	Keap1-Nrf2 axis
MoA(Mechanism of Action)	Selective targeting the Keap1-Nrf2 axis to enhance antioxidant and anti-inflammatory gene expression
Competitiveness	Dimethyl fumarate (DMF) for Multiple Sclerosis (Biogen/Almirall) Omaveloxolone for Friedreich ataxia (Reata/Biogen)
Development Stage	Candidate
Route of Administration	Oral administration

Any unauthorized distribution or reproduction of this material is strictly prohibited.